Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantationSergio Giralt, Richard E. Champlin, Michael Andreeff et al.|Blood|2001Cited by 570
Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantationSergio Giralt, Richard E. Champlin, Peter F. Thall et al.|Blood|2001Cited by 516
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trialDavid Marín, Katayoun Rezvani, Ye Li et al.|Nature Medicine|2024Cited by 452
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDSMarcos de Lima, Börje S. Andersson, Daniel R. Couriel et al.|Blood|2004Cited by 422
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemiaMarina Konopleva, Hagop Kantarjian, Peter F. Thall et al.|Haematologica|2015Cited by 121